Why is the Polynovo share price powering 6% on Tuesday?

A government grant is set to boost the medical devices company's production capability.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Polynovo share price is up 6% on Tuesday
  • The lift comes amid news the medical devices company will receive $500,000 in Victorian government funding
  • The Polynovo share price is up 40% year to date

The Polynovo Limited (ASX: PNV) share price is trading higher today amid a major announcement from the company.

Shares of the medical devices company currently trade for $2.135 each, a 5.69% gain. Earlier today, the Polynovo share price hit an intraday high of $2.20 a share, a rise of 9%

Let's find out why investors are buying Polynovo shares today.

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

What happened?

Polynovo will receive $500,000 under the Victorian government's Medtech Manufacturing Capability Program.

The company said it will use the funds to buy and upgrade manufacturing equipment for its Novosorb Synpath products which are used in treating diabetic foot ulcers, among other applications.

Polynovo chair David Williams said:

Our SynPath product offers significant health economic and healing benefits over biologic-based products in the treatment and wound closure of diabetic foot ulcers and venous leg ulcers. The much appreciated government grant will support manufacturing the new product at our Port Melbourne plant from where we will ship to the world.

Polynovo share price snapshot

The Polynovo share price is currently up almost 40% year to date.

The company's shares are significantly outperforming the S&P/ASX 200 Healthcare Index (ASX: XHJ) which has contracted 3.3% so far in 2022.

Across the broader market, the company is also beating the S&P/ASX 200 Index (ASX: XJO) year to date — it's down around 6%.

At its current share price, Polynovo has a market capitalisation of around $1.4 billion.

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »